Literature DB >> 33115686

An Interpretable Planning Bot for Pancreas Stereotactic Body Radiation Therapy.

Jiahan Zhang1, Chunhao Wang2, Yang Sheng2, Manisha Palta2, Brian Czito2, Christopher Willett2, Jiang Zhang2, P James Jensen2, Fang-Fang Yin2, Qiuwen Wu2, Yaorong Ge3, Q Jackie Wu2.   

Abstract

PURPOSE: Pancreas stereotactic body radiation therapy (SBRT) treatment planning requires planners to make sequential, time-consuming interactions with the treatment planning system to reach the optimal dose distribution. We sought to develop a reinforcement learning (RL)-based planning bot to systematically address complex tradeoffs and achieve high plan quality consistently and efficiently. METHODS AND MATERIALS: The focus of pancreas SBRT planning is finding a balance between organ-at-risk sparing and planning target volume (PTV) coverage. Planners evaluate dose distributions and make planning adjustments to optimize PTV coverage while adhering to organ-at-risk dose constraints. We formulated such interactions between the planner and treatment planning system into a finite-horizon RL model. First, planning status features were evaluated based on human planners' experience and defined as planning states. Second, planning actions were defined to represent steps that planners would commonly implement to address different planning needs. Finally, we derived a reward system based on an objective function guided by physician-assigned constraints. The planning bot trained itself with 48 plans augmented from 16 previously treated patients, and generated plans for 24 cases in a separate validation set.
RESULTS: All 24 bot-generated plans achieved similar PTV coverages compared with clinical plans while satisfying all clinical planning constraints. Moreover, the knowledge learned by the bot could be visualized and interpreted as consistent with human planning knowledge, and the knowledge maps learned in separate training sessions were consistent, indicating reproducibility of the learning process.
CONCLUSIONS: We developed a planning bot that generates high-quality treatment plans for pancreas SBRT. We demonstrated that the training phase of the bot is tractable and reproducible, and the knowledge acquired is interpretable. As a result, the RL planning bot can potentially be incorporated into the clinical workflow and reduce planning inefficiencies.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33115686      PMCID: PMC7902297          DOI: 10.1016/j.ijrobp.2020.10.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  A planning quality evaluation tool for prostate adaptive IMRT based on machine learning.

Authors:  Xiaofeng Zhu; Yaorong Ge; Taoran Li; Danthai Thongphiew; Fang-Fang Yin; Q Jackie Wu
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

Review 2.  Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.

Authors:  Susanna W L de Geus; Mariam F Eskander; Gyulnara G Kasumova; Sing Chau Ng; Tara S Kent; Joseph D Mancias; Mark P Callery; Anand Mahadevan; Jennifer F Tseng
Journal:  Cancer       Date:  2017-07-14       Impact factor: 6.860

3.  Predicting dose-volume histograms for organs-at-risk in IMRT planning.

Authors:  Lindsey M Appenzoller; Jeff M Michalski; Wade L Thorstad; Sasa Mutic; Kevin L Moore
Journal:  Med Phys       Date:  2012-12       Impact factor: 4.071

4.  Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans.

Authors:  Lulin Yuan; Yaorong Ge; W Robert Lee; Fang Fang Yin; John P Kirkpatrick; Q Jackie Wu
Journal:  Med Phys       Date:  2012-11       Impact factor: 4.071

5.  Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.

Authors:  Jim Zhong; Kirtesh Patel; Jeffrey Switchenko; Richard J Cassidy; William A Hall; Theresa Gillespie; Pretesh R Patel; David Kooby; Jerome Landry
Journal:  Cancer       Date:  2017-05-10       Impact factor: 6.860

6.  Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas.

Authors:  Jean-Claude M Rwigema; Simul D Parikh; Dwight E Heron; Michael Howell; Herbert Zeh; A James Moser; Nathan Bahary; Annette Quinn; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

7.  Data-driven approach to generating achievable dose-volume histogram objectives in intensity-modulated radiotherapy planning.

Authors:  Binbin Wu; Francesco Ricchetti; Giuseppe Sanguineti; Michael Kazhdan; Patricio Simari; Robert Jacques; Russell Taylor; Todd McNutt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

8.  Operating a treatment planning system using a deep-reinforcement learning-based virtual treatment planner for prostate cancer intensity-modulated radiation therapy treatment planning.

Authors:  Chenyang Shen; Dan Nguyen; Liyuan Chen; Yesenia Gonzalez; Rafe McBeth; Nan Qin; Steve B Jiang; Xun Jia
Journal:  Med Phys       Date:  2020-03-28       Impact factor: 4.071

9.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

10.  Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.

Authors:  Marie K Gurka; Sean P Collins; Rebecca Slack; Gary Tse; Aline Charabaty; Lisa Ley; Liam Berzcel; Siyuan Lei; Simeng Suy; Nadim Haddad; Reena Jha; Colin D Johnson; Patrick Jackson; John L Marshall; Michael J Pishvaian
Journal:  Radiat Oncol       Date:  2013-03-01       Impact factor: 3.481

View more
  6 in total

1.  Assessing the robustness of artificial intelligence powered planning tools in radiotherapy clinical settings-a phantom simulation approach.

Authors:  Martin Hito; Wentao Wang; Hunter Stephens; Yibo Xie; Ruilin Li; Fang-Fang Yin; Yaorong Ge; Q Jackie Wu; Qiuwen Wu; Yang Sheng
Journal:  Quant Imaging Med Surg       Date:  2021-12

2.  Artificial Intelligence in Radiation Therapy.

Authors:  Yabo Fu; Hao Zhang; Eric D Morris; Carri K Glide-Hurst; Suraj Pai; Alberto Traverso; Leonard Wee; Ibrahim Hadzic; Per-Ivar Lønne; Chenyang Shen; Tian Liu; Xiaofeng Yang
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2021-08-24

3.  Modeling physician's preference in treatment plan approval of stereotactic body radiation therapy of prostate cancer.

Authors:  Yin Gao; Chenyang Shen; Yesenia Gonzalez; Xun Jia
Journal:  Phys Med Biol       Date:  2022-05-26       Impact factor: 4.174

4.  The development of a deep reinforcement learning network for dose-volume-constrained treatment planning in prostate cancer intensity modulated radiotherapy.

Authors:  Damon Sprouts; Yin Gao; Chao Wang; Xun Jia; Chenyang Shen; Yujie Chi
Journal:  Biomed Phys Eng Express       Date:  2022-06-03

Review 5.  Artificial intelligence and machine learning for medical imaging: A technology review.

Authors:  Ana Barragán-Montero; Umair Javaid; Gilmer Valdés; Dan Nguyen; Paul Desbordes; Benoit Macq; Siri Willems; Liesbeth Vandewinckele; Mats Holmström; Fredrik Löfman; Steven Michiels; Kevin Souris; Edmond Sterpin; John A Lee
Journal:  Phys Med       Date:  2021-05-09       Impact factor: 2.685

6.  A hierarchical deep reinforcement learning framework for intelligent automatic treatment planning of prostate cancer intensity modulated radiation therapy.

Authors:  Chenyang Shen; Liyuan Chen; Xun Jia
Journal:  Phys Med Biol       Date:  2021-06-23       Impact factor: 3.609

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.